表紙
市場調查報告書

Gamma Secretase :開發中產品分析

Gamma Secretase - Pipeline Review, H2 2020

出版商 Global Markets Direct 商品編碼 363575
出版日期 內容資訊 英文 83 Pages
訂單完成後即時交付
價格
Gamma Secretase :開發中產品分析 Gamma Secretase - Pipeline Review, H2 2020
出版日期: 2020年10月30日內容資訊: 英文 83 Pages
簡介

本報告提供Gamma Secretase 的開發情形相關的資訊,各開發階段、藥物標的、作用機制、給藥途徑及各分子類型的分析,開發治療藥的企業概要,最新消息和新聞稿等資訊,為您概述為以下內容。

簡介

  • 調查範圍

Gamma Secretase 的概要

治療藥的開發

Gamma Secretase :開發中的產品 - 各開發階段

Gamma Secretase :開發中的產品 - 各治療範圍

Gamma Secretase :開發中的產品 - 各適應症

Gamma Secretase :開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Gamma Secretase :企業開發中的產品

Gamma Secretase :大學/機關開發中的產品

Gamma Secretase :治療藥的評估

  • 各單劑療法/聯合治療產品
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Gamma Secretase 的治療藥的開發企業

  • Amgen Inc.
  • Astellas Pharma Inc.
  • Bristol-Myers Squibb Company
  • Critical Outcome Technologies Inc.
  • FORUM Pharmaceuticals Inc.
  • Humanetics Corporation
  • Lipopharma Therapeutics SL
  • Merck & Co., Inc.
  • NeuroGenetic Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Stemline Therapeutics, Inc.
  • 大日本住友製藥
  • 武田藥品工業

藥物簡介

Gamma Secretase :暫停中的計劃

Gamma Secretase :開發中止的產品

Gamma Secretase :主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2680TDB

Summary:

According to the recently published report 'Gamma Secretase - Pipeline Review, H2 2020'; Gamma Secretase (EC 3.4.23.) pipeline Target constitutes close to 20 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Gamma Secretase (EC 3.4.23.) - Gamma secretase is a multi-subunit protease complex, itself an integral membrane protein, that cleaves single-pass transmembrane proteins at residues within the transmembrane domain. The most well-known substrate of gamma secretase is amyloid precursor protein, when cleaved by both gamma and beta secretase, produces a short 39-42 amino acid peptide called amyloid beta whose abnormally folded fibrillar form is the primary component of amyloid plaques found in the brains of Alzheimer's disease patients. Gamma secretase is also critical in the related processing of the Notch protein.

The report 'Gamma Secretase - Pipeline Review, H2 2020' outlays comprehensive information on the Gamma Secretase (EC 3.4.23.) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 3, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Ear Nose Throat Disorders, Non Malignant Disorders, Cardiovascular and Metabolic Disorders which include indications Alzheimer's Disease, Adenoid Cystic Carcinoma (ACC), Benign Tumor, Hearing Disorders, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Soft Tissue Sarcoma, Triple-Negative Breast Cancer (TNBC), Acute Sensorineural Hearing Loss, Bile Duct Cancer (Cholangiocarcinoma), Burkitt Lymphoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Congestive Heart Failure (Heart Failure), Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Leiomyosarcoma, Leukemia, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Natural Killer Cell Lymphomas, Obesity, Solid Tumor and T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Gamma Secretase (EC 3.4.23.)
  • The report reviews Gamma Secretase (EC 3.4.23.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Gamma Secretase (EC 3.4.23.) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Gamma Secretase (EC 3.4.23.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Gamma Secretase (EC 3.4.23.) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Gamma Secretase (EC 3.4.23.)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Gamma Secretase (EC 3.4.23.) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Gamma Secretase (EC 3.4.23.) - Overview
  • Gamma Secretase (EC 3.4.23.) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Gamma Secretase (EC 3.4.23.) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Gamma Secretase (EC 3.4.23.) - Companies Involved in Therapeutics Development
  • Adipo Therapeutics LLC
  • AlzeCure Pharma AB
  • Astellas Pharma Inc
  • Audion Therapeutics BV
  • Ayala Pharmaceuticals Inc
  • Eli Lilly and Co
  • Everfront Biotech Inc
  • F. Hoffmann-La Roche Ltd
  • Lipopharma Therapeutics SL
  • Merck & Co Inc
  • NeuroGenetic Pharmaceuticals Inc
  • Pharchoice Therapeutics Inc
  • Pipeline Therapeutics Inc
  • SpringWorks Therapeutics Inc
  • Gamma Secretase (EC 3.4.23.) - Drug Profiles
  • ACD-679 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ACD-680 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AL-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AL-102 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • crenigacestat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dibenzazepine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EF-005 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy to Activate PSEN1 for Heart Failure - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSI-34 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LP-226A1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • LY-3056480 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NGP-555 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nirogacestat hydrobromide - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peptides to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PIPE-505 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RO-7185876 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Beta Secretase and Gamma Secretase for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit Gamma Secretase for Hearing Loss - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit PSEN1 for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Modulate Gamma Secretase for Alzheimer's Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gamma Secretase (EC 3.4.23.) - Dormant Products
  • Gamma Secretase (EC 3.4.23.) - Discontinued Products
  • Gamma Secretase (EC 3.4.23.) - Product Development Milestones
  • Featured News & Press Releases
  • Sep 18, 2020: Ayala Pharmaceuticals presents positive interim data from phase 2 ACCURACY trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma with notch activating mutations at ESMO 2020
  • Sep 16, 2020: SpringWorks Therapeutics announces collaboration with Children's Oncology Group to conduct a phase 2 clinical trial of nirogacestat in pediatric patients with desmoid tumors and reports publication of nirogacestat case series in pediatric/young adult desmoid tumor patients
  • Sep 14, 2020: Ayala Pharmaceuticals to host virtual KOL event reviewing interim data presented at ESMO 2020 from ongoing phase 2 accuracy trial of AL101 for the treatment of recurrent/metastatic adenoid cystic carcinoma
  • Jul 27, 2020: Ayala Pharmaceuticals to present updated data from ongoing phase 2 ACCURACY trial of AL101 for the treatment of R/M adenoid cystic carcinoma at the European Society for Medical Oncology (ESMO) virtual congress 2020
  • Jul 23, 2020: Pipeline Therapeutics initiates Phase 1/2a clinical trial of PIPE-505 in sensorineural hearing loss
  • Jul 22, 2020: SpringWorks Therapeutics announces full enrollment of phase 3 DeFi trial evaluating nirogacestat in adult patients with desmoid tumors
  • Jun 22, 2020: SpringWorks Therapeutics announces dosing of first patient in phase 1b combination study evaluating Nirogacestat and GlaxoSmithKline's Belantamab Mafodotin for the treatment of Relapsed or Refractory Multiple Myeloma
  • Mar 18, 2020: SpringWorks Therapeutics announces issuance of new U.S. composition of matter patent to polymorphic form of Nirogacestat, extending patent protection into 2039
  • Mar 03, 2020: Ayala Pharmaceuticals granted U.S. FDA Fast Track Designation for AL101 for the treatment of recurrent or metastatic adenoid cystic carcinoma
  • Dec 09, 2019: Researchers present preclinical data showing synergistic activity of Springworks Therapeutics gamma secretase inhibitor (Nirogacestat) with glaxosmithkline's BCMA antibody-drug conjugate (Belantamab Mafodotin) at the American Society of Hematology (ASH ) Annual Meeting
  • Sep 30, 2019: Ayala Pharmaceuticals presents encouraging preliminary safety and efficacy data in patients with Recurrent/Metastatic Adenoid Cystic Carcinoma with progressing disease and notch activating mutations from ongoing phase 2 clinical trial at ESMO
  • Sep 26, 2019: SpringWorks receives orphan status for nirogacestat in Europe
  • Sep 19, 2019: Ayala Pharmaceuticals announces presentation at the European Society for Medical Oncology (ESMO)
  • Aug 30, 2019: SpringWorks receives breakthrough status for desmoid tumour drug
  • May 20, 2019: Ayala Pharmaceuticals to present at ASCO Annual Meeting on investigational drug AL101 in adenoid cystic carcinoma and triple negative breast cancer
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020 (Contd..1), H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by Adipo Therapeutics LLC, H2 2020
  • Pipeline by AlzeCure Pharma AB, H2 2020
  • Pipeline by Astellas Pharma Inc, H2 2020
  • Pipeline by Audion Therapeutics BV, H2 2020
  • Pipeline by Ayala Pharmaceuticals Inc, H2 2020
  • Pipeline by Eli Lilly and Co, H2 2020
  • Pipeline by Everfront Biotech Inc, H2 2020
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2020
  • Pipeline by Lipopharma Therapeutics SL, H2 2020
  • Pipeline by Merck & Co Inc, H2 2020
  • Pipeline by NeuroGenetic Pharmaceuticals Inc, H2 2020
  • Pipeline by Pharchoice Therapeutics Inc, H2 2020
  • Pipeline by Pipeline Therapeutics Inc, H2 2020
  • Pipeline by SpringWorks Therapeutics Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020